Figure 10From: Hitting bacteria at the heart of the central dogma: sequence-specific inhibitionThe first FDA-approved antisense drug. Structure of the 21-mer phosphorothioate, fomivirsen (brand name Vitravene, illustration from [223]). The patient target group for this drug is rather small, and it was taken off the market by the manufacturer in 2002 due to poor sales [224].Back to article page